[go: up one dir, main page]

PH12013501105A1 - Tomm34 peptides and vaccines including the same - Google Patents

Tomm34 peptides and vaccines including the same

Info

Publication number
PH12013501105A1
PH12013501105A1 PH1/2013/501105A PH12013501105A PH12013501105A1 PH 12013501105 A1 PH12013501105 A1 PH 12013501105A1 PH 12013501105 A PH12013501105 A PH 12013501105A PH 12013501105 A1 PH12013501105 A1 PH 12013501105A1
Authority
PH
Philippines
Prior art keywords
peptides
same
vaccines including
present
tomm34
Prior art date
Application number
PH1/2013/501105A
Other languages
English (en)
Inventor
Yusuke Nakamura
Gaku Nakayama
Ryuji Osawa
Takuya Tsunoda
Tomohisa Watanabe
Sachiko Yoshimura
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of PH12013501105A1 publication Critical patent/PH12013501105A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G01N33/57557—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PH1/2013/501105A 2010-12-02 2011-11-25 Tomm34 peptides and vaccines including the same PH12013501105A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41918110P 2010-12-02 2010-12-02
PCT/JP2011/006551 WO2012073459A1 (fr) 2010-12-02 2011-11-25 Peptides tomm34 et vaccins les comprenant

Publications (1)

Publication Number Publication Date
PH12013501105A1 true PH12013501105A1 (en) 2013-08-05

Family

ID=46171433

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/501105A PH12013501105A1 (en) 2010-12-02 2011-11-25 Tomm34 peptides and vaccines including the same

Country Status (23)

Country Link
US (3) US9125849B2 (fr)
EP (1) EP2646546B1 (fr)
JP (2) JP6064186B2 (fr)
KR (1) KR102004900B1 (fr)
CN (2) CN105111281A (fr)
AR (1) AR084095A1 (fr)
AU (1) AU2011336019B2 (fr)
BR (1) BR112013013158B1 (fr)
CA (1) CA2819463C (fr)
CO (1) CO6862100A2 (fr)
DK (1) DK2646546T3 (fr)
EA (1) EA028216B1 (fr)
ES (1) ES2677118T3 (fr)
IL (1) IL226068B (fr)
MX (1) MX344586B (fr)
MY (1) MY166516A (fr)
NZ (1) NZ611361A (fr)
PH (1) PH12013501105A1 (fr)
SG (2) SG190407A1 (fr)
TW (1) TWI618541B (fr)
UA (1) UA110119C2 (fr)
WO (1) WO2012073459A1 (fr)
ZA (1) ZA201303886B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784862T3 (es) 2012-09-11 2020-10-01 Oncotherapy Science Inc Péptidos UBE2T y vacunas que los contienen
JP2015228191A (ja) * 2014-06-03 2015-12-17 カシオ計算機株式会社 コンテンツ出力システム、コンテンツ出力方法、コンテンツ出力プログラム、および通信端末
CN107534710B (zh) * 2016-02-29 2019-07-23 京瓷办公信息系统株式会社 电子设备以及标记处理方法
MX2019008878A (es) 2017-01-25 2020-02-13 Ose Immunotherapeutics Metodo para fabricar una emulsion estable para suministro de peptidos.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
JPH04504416A (ja) 1989-02-17 1992-08-06 コセルコ・ミモトープス・ピィ・ティ・ワイ．エル・ティ・ディ． ペプチドの使用方法と合成方法
CA2158655A1 (fr) * 1993-03-19 1994-09-29 Max L. Birnstiel Methode de preparation de vaccins contre le cancer
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO2001049310A1 (fr) 2000-01-03 2001-07-12 Argonex Pharmaceuticals, Inc. Peptides derives d'oncogene c-ski pour la prevention, le traitement et le diagnostic du cancer
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20040181344A1 (en) 2002-01-29 2004-09-16 Massachusetts Institute Of Technology Systems and methods for providing diagnostic services
ATE500326T1 (de) * 2002-06-06 2011-03-15 Oncotherapy Science Inc Gene und proteine mit bezug zu menschlichem kolonkrebs
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
ES2327040T3 (es) 2002-09-12 2009-10-23 Oncotherapy Science, Inc. Peptidos kdr y vacunas que los contienen.
ATE401575T1 (de) 2003-01-06 2008-08-15 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
US20080274129A1 (en) * 2003-04-18 2008-11-06 Fikes John D Hla-A2 Tumor Associated Antigen Peptides and Compositions
BRPI0613970B8 (pt) * 2005-07-27 2021-05-25 Oncotherapy Science Inc composição para o tratamento ou para a prevenção de câncer de cólon compreende uma quantidade farmaceuticamente eficaz de um sirna contra um polinucleotídeo de tom 34
DK1760089T3 (da) * 2005-09-05 2009-11-16 Immatics Biotechnologies Gmbh Tumor-associeret peptides bindende til human leukocyte antigen (HLA) class I eller II molecules og relateret anti-cancer vaccine
TWI494319B (zh) * 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
TWI434853B (zh) * 2007-04-11 2014-04-21 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
RU2600888C2 (ru) * 2009-03-18 2016-10-27 Онкотерапи Сайенс, Инк. Пептиды neil3 и включающие их вакцины

Also Published As

Publication number Publication date
TWI618541B (zh) 2018-03-21
JP6064186B2 (ja) 2017-01-25
EP2646546A1 (fr) 2013-10-09
EP2646546A4 (fr) 2015-12-23
EP2646546B1 (fr) 2018-05-16
SG190407A1 (en) 2013-06-28
CN103339253A (zh) 2013-10-02
CA2819463C (fr) 2018-10-23
AU2011336019B2 (en) 2016-07-07
DK2646546T3 (en) 2018-08-06
IL226068A0 (en) 2013-06-27
WO2012073459A1 (fr) 2012-06-07
IL226068B (en) 2019-01-31
CN103339253B (zh) 2015-09-09
EA028216B1 (ru) 2017-10-31
KR20130121910A (ko) 2013-11-06
BR112013013158B1 (pt) 2020-04-28
SG10201509823WA (en) 2015-12-30
CN105111281A (zh) 2015-12-02
CA2819463A1 (fr) 2012-06-07
US20150374810A1 (en) 2015-12-31
AR084095A1 (es) 2013-04-17
EA201390811A1 (ru) 2013-12-30
JP2014506114A (ja) 2014-03-13
JP2016222676A (ja) 2016-12-28
MX344586B (es) 2016-12-20
AU2011336019A1 (en) 2013-07-04
US20170198010A1 (en) 2017-07-13
CO6862100A2 (es) 2014-02-10
US20140023671A1 (en) 2014-01-23
MY166516A (en) 2018-07-05
US9125849B2 (en) 2015-09-08
US9585948B2 (en) 2017-03-07
ZA201303886B (en) 2014-03-26
KR102004900B1 (ko) 2019-07-29
ES2677118T3 (es) 2018-07-30
NZ611361A (en) 2014-10-31
BR112013013158A2 (pt) 2017-08-01
TW201225973A (en) 2012-07-01
UA110119C2 (xx) 2015-11-25
MX2013006014A (es) 2013-07-29

Similar Documents

Publication Publication Date Title
EP3412304A3 (fr) Épitopes agonistes hla-a24 de l'oncoprotéine muc1-c et compositions et procédés d'utilisation
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PH12014500720A1 (en) Topk peptides and vaccines including the same
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
MX2009007261A (es) Vacuna de peptido foxp3.
GB201019331D0 (en) Methods for the diagnosis and treatment of cancer based on AVL9
MX2012008657A (es) Peptidos melk modificados y vacunas que contienen los mismos.
EP3868778A3 (fr) Peptides cdc45l et vaccins les comportant
MY166516A (en) Tomm34 peptides and vaccines including the same
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
MX2011004176A (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
EP2513136A4 (fr) Peptides tmem22 et vaccins les comprenant
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
MX342000B (es) Peptidos ect2 y vacunas que los incluyen.
EP4047009A3 (fr) Peptides à épitope wdrpuh et vaccins les contenant
TH158366A (th) Topk เปปไทด์ และวัคซีนที่รวมถึงสิ่งเดียวกันนั้น
TH143303A (th) Tomm34 เปปไทด์ และ วัคซีนที่บรรจุสิ่งเดียวกันนี้
PH12012501935A1 (en) Ect2 peptides and vaccines including the same